An integrated approach to precision oncology

Order a test

OncoHost is advancing a new paradigm in precision oncology

Our PROphet® platform combines bioinformatics, system biology, proteomic pattern recognition and machine learning to assign a PROphet® score, a measure of the predicted clinical benefit from
PD-1/PD-L1 inhibitors correlated to the patient’s overall survival, and list clinical evidence-based treatment considerations.
Understanding the interplay between

Cancer, Patient & Therapy

A new approach to managing PD-1/PD-L1 inhibitor therapeutic strategies

Blood-based test

PROphet® Report

clinical insights

Clinical evidence-
based treatment considerations

Plasma Proteomic
Pattern Recognition

Analyzing the biological interplay between the patient, tumor, and therapy can:
Enable early prediction of clinical benefit from PD-1/PD-L1 inhibitors
Provide actionable clinical insights and optimal therapy choices
Read more